145 related articles for article (PubMed ID: 6122893)
1. Sustained suppression of testosterone production by the luteinising-hormone releasing-hormone agonist buserelin in patients with advanced prostate carcinoma. A new therapeutic approach?
Borgmann V; Hardt W; Schmidt-Gollwitzer M; Adenauer H; Nagel R
Lancet; 1982 May; 1(8281):1097-9. PubMed ID: 6122893
[TBL] [Abstract][Full Text] [Related]
2. Treatment with gonadotrophin releasing hormone analogue in advanced prostatic cancer.
Waxman JH; Wass JA; Hendry WF; Whitfield HN; Besser GM; Malpas JS; Oliver RT
Br Med J (Clin Res Ed); 1983 Apr; 286(6374):1309-12. PubMed ID: 6404441
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of serum androgen levels by chronic intranasal and subcutaneous administration of a potent luteinizing hormone-releasing hormone (LH-RH) agonist in adult men.
Faure N; Labrie F; Lemay A; Bélanger A; Gourdeau Y; Laroche B; Robert G
Fertil Steril; 1982 Mar; 37(3):416-24. PubMed ID: 6800852
[TBL] [Abstract][Full Text] [Related]
4. Suppression of testicular steroidogenesis by the GnRH agonistic analogue Buserelin (HOE-766) in patients with prostatic cancer: studies in relation to dose and route of administration.
Tolis G; Faure N; Koutsilieris M; Lemay A; Klioze S; Yakabow A; Fazekas AT
J Steroid Biochem; 1983 Jul; 19(1C):995-8. PubMed ID: 6411994
[TBL] [Abstract][Full Text] [Related]
5. Treatment with a luteinising-hormone-releasing-hormone analogue (buserelin) in premenopausal patients with metastatic breast cancer.
Klijn JG; de Jong FH
Lancet; 1982 May; 1(8283):1213-6. PubMed ID: 6122975
[TBL] [Abstract][Full Text] [Related]
6. Endocrine studies with a gonadotropin-releasing hormone analogue to achieve withdrawal of testosterone in prostate carcinoma patients.
Wenderoth UK; Happ J; Krause U; Adenauer H; Jacobi GH
Eur Urol; 1982; 8(6):343-7. PubMed ID: 6814918
[TBL] [Abstract][Full Text] [Related]
7. Results of a Dutch Phase II trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer.
Debruyne FM; Karthaus HF; Schröder FH; de Voogt HJ; de Jong FH; Klijn JG
Prog Clin Biol Res; 1985; 185A():251-70. PubMed ID: 3929265
[No Abstract] [Full Text] [Related]
8. Comparison of the efficacy of subcutaneous and nasal spray buserelin treatment in suppression of testicular steroidogenesis in men with prostate cancer.
Rajfer J; Handelsman DJ; Crum A; Steiner B; Peterson M; Swerdloff RS
Fertil Steril; 1986 Jul; 46(1):104-10. PubMed ID: 3087785
[TBL] [Abstract][Full Text] [Related]
9. Long term follow-up of patients with advanced prostatic cancer treated with nasal buserelin.
Falkson CI; Falkson G; Falkson HC
Ann Oncol; 1991 Apr; 2(4):303-4. PubMed ID: 1907843
[TBL] [Abstract][Full Text] [Related]
10. Long term treatment with luteinising hormone releasing hormone agonists and maintenance of serum testosterone to castration concentrations.
Labrie F; Dupont A; Belanger A; Lachance R; Giguere M
Br Med J (Clin Res Ed); 1985 Aug; 291(6492):369-70. PubMed ID: 3926197
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic potential of the LHRH agonist, ICI 118630, in the treatment of advanced prostatic carcinoma.
Walker KJ; Nicholson RI; Turkes AO; Turkes A; Griffiths K; Robinson M; Crispin Z; Dris S
Lancet; 1983 Aug; 2(8347):413-5. PubMed ID: 6135908
[TBL] [Abstract][Full Text] [Related]
12. Response of circulating gonadotropin levels to GnRH agonist treatment in prostatic cancer.
Huhtaniemi I; Venho P; Jacobi G; Rannikko S
J Androl; 1991; 12(1):46-53. PubMed ID: 1901309
[TBL] [Abstract][Full Text] [Related]
13. Zoladex: a sustained-release, monthly luteinizing hormone-releasing hormone analogue for the treatment of advanced prostate cancer.
Ahmann FR; Citrin DL; deHaan HA; Guinan P; Jordan VC; Kreis W; Scott M; Trump DL
J Clin Oncol; 1987 Jun; 5(6):912-7. PubMed ID: 2953870
[TBL] [Abstract][Full Text] [Related]
14. [Treatment of advanced cancer of the prostate with an analog of LHRH, buserelin].
Wenderoth UK; Jacobi GH
Ann Urol (Paris); 1986; 20(2):95-7. PubMed ID: 3087269
[TBL] [Abstract][Full Text] [Related]
15. Treatment of prostatic cancer with a gonadotropin-releasing hormone agonist analog: acute and long term effects on endocrine functions of testis tissue.
Huhtaniemi I; Nikula H; Rannikko S
J Clin Endocrinol Metab; 1985 Oct; 61(4):698-704. PubMed ID: 2993345
[TBL] [Abstract][Full Text] [Related]
16. Chronic treatment with the gonadotropin-releasing hormone agonist D-Ser(TBU)6-EA10-LRH for contraception in women and men.
Nillius SJ; Bergquist C; Wide L
Int J Fertil; 1980; 25(3):239-46. PubMed ID: 6108935
[TBL] [Abstract][Full Text] [Related]
17. The first clinical use of depot buserelin for advanced prostatic carcinoma.
Waxman JH; Sandow J; Man A; Barnett MJ; Hendry WF; Besser GM; Oliver RT; Magill PJ
Cancer Chemother Pharmacol; 1986; 18(2):174-5. PubMed ID: 3098445
[TBL] [Abstract][Full Text] [Related]
18. Prostatic cancer: treatment with long-acting LHRH analogue.
Williams G; Allen JM; O'Shea JP; Mashiter K; Doble A; Bloom SR
Br J Urol; 1983 Dec; 55(6):743-6. PubMed ID: 6228283
[TBL] [Abstract][Full Text] [Related]
19. Fourteen-day versus twenty-one-day regimens of intermittent intranasal luteinizing hormone-releasing hormone agonist combined with an oral progestogen as antiovulatory contraceptive approach.
Lemay A; Faure N
J Clin Endocrinol Metab; 1986 Dec; 63(6):1379-85. PubMed ID: 2946711
[TBL] [Abstract][Full Text] [Related]
20. Endocrine and clinical effects of leuprolide in prostatic cancer.
Vance MA; Smith JA
Clin Pharmacol Ther; 1984 Sep; 36(3):350-4. PubMed ID: 6432399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]